Hi @slymeat, your straw about PIQs latest investor presentation is fairly bullish on how the company is setup for 2022. I have been a holder for awhile now IRL so I am hopeful that this is the year it all works out for them, however I'd like to hear if there are any key indicators that will be a deal breaker for you. The reason is PIQ have been in a holding pattern with distribution in Italy and Israel for some time now. The below is from an investor presentation in Nov 2020. LINK

It's been a tough time for healthcare companies in the midst of a global pandemic, but at some point they need to start delivering. The other risk I see here is these are 2 year agreements that so far haven't delivered for either party, so there is a chance that if the end of the year rolls around they may not be renewed.

I think the product is very beneficial, particularly if they can get approval for the Endometriosis test that is in the works. One of my main issues as a relatively new investor is that I get caught up in the story and have been caught up in a few companies now where management keep making promises that they continue to miss. I am working through how I evaluate this for myself, and know that you hold some blue sky companies and am interested to hear what your process is for setting checkpoints for your thesis.

Cheers